Mania associated with antidepressant treatment: comprehensive meta-analytic review

Department of Psychiatry and Neuroscience Program, Harvard Medical School and McLean Division of Massachusetts General Hospital, Boston, MA, USA.
Acta Psychiatrica Scandinavica (Impact Factor: 5.55). 12/2009; 121(6):404-14. DOI: 10.1111/j.1600-0447.2009.01514.x
Source: PubMed

ABSTRACT To review available data pertaining to risk of mania-hypomania among bipolar (BPD) and major depressive disorder (MDD) patients with vs. without exposure to antidepressant drugs (ADs) and consider effects of mood stabilizers.
Computerized searching yielded 73 reports (109 trials, 114 521 adult patients); 35 were suitable for random effects meta-analysis, and multivariate-regression modeling included all available trials to test for effects of trial design, AD type, and mood-stabilizer use.
The overall risk of mania with/without ADs averaged 12.5%/7.5%. The AD-associated mania was more frequent in BPD than MDD patients, but increased more in MDD cases. Tricyclic antidepressants were riskier than serotonin-reuptake inhibitors (SRIs); data for other types of ADs were inconclusive. Mood stabilizers had minor effects probably confounded by their preferential use in mania-prone patients.
Use of ADs in adults with BPD or MDD was highly prevalent and moderately increased the risk of mania overall, with little protection by mood stabilizers.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Obsessive-compulsive disorder (OCD) is a leading cause of disability, which is gaining increased recognition as evidenced by the disorder’s own category of related disorders in the DSM-5. Nonetheless, OCD remains undertreated despite the availability of well-researched and effective treatment options. Selective serotonin reuptake inhibitors (SSRIs) are a typical first-line approach, but require 4-8 weeks to become fully effective and often result in only a partial response. Underdosing is a common problem, since higher doses are usually required for OCD than for antidepressant effects. Sexual side effects are a common problem and may result in discontinuation. For partial responders, SRIs (including SSRIs and the tricyclic clomipramine) are often augmented with neuroleptics, but new research calls into question the benefits of this approach. Exposure and response/ritual prevention (Ex/RP) is a more effective method for augmenting antidepressant medications. New research indicates that Ex/RP can be made more effective by augmentation with the cognitive enhancer D-cycloserine.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: There is an increasing use of ayahuasca for recreational purposes. Furthermore, there is a growing evidence for the antidepressant properties of its components. However, there are no reports on the effects of this substance in the psychiatric setting. Harmaline, one of the main components of ayahuasca, is a selective and reversible MAO-A inhibitor and a serotonin reuptake inhibitor. We present the case of a man with bipolar disorder who had a manic episode after an ayahuasca consumption ritual. This patient had had at least one hypomanic episode in the past and is currently depressed. We discuss the diagnostic repercussion of this manic episode. There is lack of specificity in the diagnosis of substance-induced mental disorder. The knowledge of the pharmacodynamic properties of ayahuasca consumption allows a more physiopathological approach to the diagnosis of the patient.
    02/2015; 3:4. DOI:10.1186/s40345-014-0020-y

Full-text (2 Sources)

Available from
May 27, 2014